Vendor Intelligence Report: Polaris Peptides

Executive summary

Across 99 Finnrick lab tests, Polaris Peptides shows 64 pass / 27 fail — an overall pass rate of 65%. The record does not read like a simple fake-peptide case; it reads like an uneven catalog. Tirzepatide is the strongest tested use case, semaglutide is more middle-of-pack, BPC-157 is a poor choice, and retatrutide needs a separate dosing-consistency warning. Under stricter grading, the vendor’s ratings thin out further.

The company picture is also narrower than the branding implies. Nevada filings tie Polaris Peptides to a recently formed LLC rather than a standalone entity, while the public storefront keeps ownership off-page and sits behind a login wall that blocks unauthenticated access to catalog, pricing, and COAs. The address trail, sister-brand copy, parked domain, affiliate-storefront lead, and clone site all matter for verification.

COA risk is handled as a verification problem, not an accusation against Polaris. The report traces Polaris paperwork to TrustPointe Analytics, a real COA provider with LIMS verification, but one where no ISO/IEC 17025 accreditation claim surfaced and where TrustPointe itself disclosed a falsified-COA incident involving an unnamed vendor. Operationally, Polaris also combines government-ID checkout friction with a complaint file that includes a blacklist-threat allegation and a single-order fulfillment watch item.

Inside the full report:

• Per-product Finnrick pass/fail rates, methodology-divergence charts, and Appendix A lab data for all 9 products
• Nevada SOS filings and trade-name analysis for Polaris Bioactives LLC versus Polaris Peptides
• Corporate and domain network map covering the sister skincare brand, parked USA domain, affiliated storefront lead, and impostor clone
• Retatrutide quantity-accuracy timeline showing overdose, underdose, and later recovery phases
• TrustPointe COA provider review, LIMS verification guidance, and falsified-COA incident analysis
• Customer-service complaint dossier covering Reddit, Trustpilot, and the April–May 2026 fulfillment watch item

Risk assessment

• BPC-157 product-quality risk — high: BPC-157 is the weakest tested Polaris line: 12 tests, 3 pass / 9 fail, Finnrick rating 33.42%.
• Retatrutide dosing-consistency risk — high: Retatrutide has 27 tests, 21 pass / 6 fail, 78.03%, but the batch timeline documents large quantity swings, including +28.9% and -32.4% extremes, before later improvement.
• CJC-1295 and Survodutide product-quality uncertainty — medium: CJC-1295 is 31.07% on 4 tests and Survodutide is 53.25% on 5 tests; samples are thin but weak enough to affect product choice.
• Customer-service retaliation risk — high: A Reddit/Trustpilot-linked defective-vial complaint alleged a blacklist threat; Polaris’s captured Reddit reply did not deny the allegation.
• Privacy and identity-data exposure — medium: Credit-card checkout uses Token of Trust identity verification collecting government ID and selfie data in a gray-market purchase flow.
• COA and lab-verification risk — medium: TrustPointe is a real COA provider with LIMS verification, but no ISO/IEC 17025 accreditation claim was found and TrustPointe disclosed a falsified-COA incident by an unnamed vendor.
• Copycat and brand-confusion risk — medium: polaris-peptide.com cloned Polaris wording on different infrastructure; Polaris does not appear to publish a complete official-channel or authorized-reseller list.
• Corporate-transparency and accountability risk — medium: The LLC and manager are identifiable in Nevada records, but the main site does not name management and the registered address is a virtual mailbox.